Literature DB >> 22090270

Quality of life in European patients with Addison's disease: validity of the disease-specific questionnaire AddiQoL.

Marianne Øksnes1, Sophie Bensing, Anna-Lena Hulting, Olle Kämpe, Annika Hackemann, Gesine Meyer, Klaus Badenhoop, Corrado Betterle, Anna Parolo, Roberta Giordano, Alberto Falorni, Lucyna Papierska, Wojciech Jeske, Anna A Kasperlik-Zaluska, V Krishna K Chatterjee, Eystein S Husebye, Kristian Løvås.   

Abstract

CONTEXT: Patients with Addison's disease (AD) self-report impairment in specific dimensions on well-being questionnaires. An AD-specific quality-of-life questionnaire (AddiQoL) was developed to aid evaluation of patients.
OBJECTIVE: We aimed to translate and determine construct validity, reliability, and concurrent validity of the AddiQoL questionnaire.
METHODS: After translation, the final versions were tested in AD patients from Norway (n = 107), Sweden (n = 101), Italy (n = 165), Germany (n = 200), and Poland (n = 50). Construct validity was examined by exploratory factor analysis and Rasch analysis, aiming at unidimensionality and fit to the Rasch model. Reliability was determined by Cronbach's coefficient-α and Person separation index. Longitudinal reliability was tested by differential item functioning in stable patient subgroups. Concurrent validity was examined in Norwegian (n = 101) and Swedish (n = 107) patients.
RESULTS: Exploratory factor analysis and Rasch analysis identified six items with poor psychometric properties. The 30 remaining items fitted the Rasch model and proved unidimensional, supported by appropriate item and person fit residuals and a nonsignificant χ(2) probability. Crohnbach's α-coefficient 0.93 and Person separation index 0.86 indicate high reliability. Longitudinal reliability was excellent. Correlation with Short Form-36 and Psychological General Well-Being Index scores was high. A shorter subscale comprising eight items also proved valid and reliable. Testing of AddiQoL-30 in this large patient cohort showed significantly worse scores with increasing age and in women compared with men but no difference between patients with isolated AD and those with concomitant diseases.
CONCLUSION: The validation process resulted in a revised 30-item AddiQoL questionnaire and an eight-item AddiQoL short version with good psychometric properties and high reliability.

Entities:  

Mesh:

Year:  2011        PMID: 22090270     DOI: 10.1210/jc.2011-1901

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  30 in total

1.  Prednisolone or hydrocortisone replacement in patients with corticotrope deficiency fasting during Ramadan result in similar risks of complications and quality of life: a randomized double-blind controlled trial.

Authors:  Melika Chihaoui; Wafa Mimita; Ibtissem Oueslati; Ons Rejeb; Zohra Ben Amor; Wafa Grira; Meriem Yazidi; Fatma Chaker
Journal:  Endocrine       Date:  2019-09-24       Impact factor: 3.633

Review 2.  Adrenal insufficiency.

Authors:  Stefanie Hahner; Richard J Ross; Wiebke Arlt; Irina Bancos; Stephanie Burger-Stritt; David J Torpy; Eystein S Husebye; Marcus Quinkler
Journal:  Nat Rev Dis Primers       Date:  2021-03-11       Impact factor: 52.329

3.  Continuous subcutaneous hydrocortisone infusion in a woman with secondary adrenal insufficiency.

Authors:  Francesca Cardini; Elisabetta Torlone; Vittorio Bini; Alberto Falorni
Journal:  Endocrine       Date:  2018-10-23       Impact factor: 3.633

4.  Improvement of anthropometric and metabolic parameters, and quality of life following treatment with dual-release hydrocortisone in patients with Addison's disease.

Authors:  Roberta Giordano; Federica Guaraldi; Elisa Marinazzo; Federica Fumarola; Alessia Rampino; Rita Berardelli; Ioannis Karamouzis; Manuela Lucchiari; Tilde Manetta; Giulio Mengozzi; Emanuela Arvat; Ezio Ghigo
Journal:  Endocrine       Date:  2015-07-17       Impact factor: 3.633

5.  Towards the tailoring of glucocorticoid replacement in adrenal insufficiency: the Italian Society of Endocrinology Expert Opinion.

Authors:  A M Isidori; G Arnaldi; M Boscaro; A Falorni; C Giordano; R Giordano; R Pivonello; C Pozza; E Sbardella; C Simeoli; C Scaroni; A Lenzi
Journal:  J Endocrinol Invest       Date:  2019-11-26       Impact factor: 4.256

6.  Preliminary results from whole-genome expression analysis in patients with secondary adrenal insufficiency treated with modified-release hydrocortisone.

Authors:  Tania Pilli; Sandro Cardinale; Silvia Cantara; Gilda Dalmazio; Raffaella Forleo; Marco Capezzone; Cristian Bassi; Massimo Negrini; Manuela Ferracin; Maria Grazia Castagna
Journal:  Endocrine       Date:  2021-01-08       Impact factor: 3.633

Review 7.  Dual-release Hydrocortisone in Addison's Disease - A Review of the Literature.

Authors:  Roberta Giordano; Federica Guaraldi; Rita Berardelli; Ioannis Karamouzis; Valentina D'Angelo; Clizia Zichi; Silvia Grottoli; Ezio Ghigo; Emanuela Arvat
Journal:  Eur Endocrinol       Date:  2014-02-28

8.  A Phase 2 Study of Continuous Subcutaneous Hydrocortisone Infusion in Adults With Congenital Adrenal Hyperplasia.

Authors:  Aikaterini A Nella; Ashwini Mallappa; Ashley F Perritt; Verena Gounden; Parag Kumar; Ninet Sinaii; Lori-Ann Daley; Alexander Ling; Chia-Ying Liu; Steven J Soldin; Deborah P Merke
Journal:  J Clin Endocrinol Metab       Date:  2016-09-28       Impact factor: 5.958

9.  Longitudinal AddiQoL scores may identify higher risk for adrenal crises in Addison's disease.

Authors:  Gesine Meyer; Maike Koch; Eva Herrmann; Jörg Bojunga; Klaus Badenhoop
Journal:  Endocrine       Date:  2018-01-31       Impact factor: 3.633

10.  Long-term use of continuous subcutaneous hydrocortisone infusion therapy in patients with congenital adrenal hyperplasia.

Authors:  Ashwini Mallappa; Aikaterini A Nella; Ninet Sinaii; Hamsini Rao; Verena Gounden; Ashley F Perritt; Parag Kumar; Alexander Ling; Chia-Ying Liu; Steven J Soldin; Deborah P Merke
Journal:  Clin Endocrinol (Oxf)       Date:  2018-08-08       Impact factor: 3.478

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.